ATLANTA, Aug. 29, 2007 -- Atlanta-based Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, announced today that it has signed a licensing agreement with Phase 2 Discovery, a drug development company affiliated with researchers at the University of Cincinnati School of Medicine, Department of Psychiatry, for ...
From: biz.yahoo.com
Tikvah Therapeutics Signs Agreement to Develop and Commercialize LY156735, a Second Generation Melatonin Agonist, for ...
Posted by Ruslan Abuzant at 6:45 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment